{"analyses":[{"ciNumSides":"TWO_SIDED","groupIds":["OG000"],"nonInferiorityType":"OTHER","pValue":"0.67","paramType":"Hazard Ratio (HR)","paramValue":"0.81","statisticalMethod":"Regression, Cox"},{"ciNumSides":"TWO_SIDED","groupIds":["OG000"],"nonInferiorityType":"OTHER","pValue":"0.11","paramType":"C-statistic","paramValue":"0.71","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.02","value":"0.04"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Prediction efficacy is estimated using a hazard ratio (HR) and C-statistic (C-stat).Overall survival is defined as the span of time from day 1 of therapy to date of death from any cause (measured in months). Results are pooled with subjects from a pilot RDRC study for a total of 25 subjects analyzed. FLT uptake in the tumor is a dynamic process that involves facilitated diffusion in and out of the cell and molecular changes in FLT. The rate K-FLT, measured in mL/g/min, is a composite of the rate of transport of FLT from blood into the tissue and the transfer from tissue back into the blood, as well as the rate of molecular change of FLT.","dispersionType":"Standard Deviation","groups":[{"description":"Subjects receive 2 18F-Fluorothymidine PET scans\n\n* Scan 1 at baseline (within 30 days prior to the start of chemotherapy and radiation therapy)\n* Scan 2 between fraction 5 and 6 of radiation therapy (after 10 Gray of radiation)\n\nF-18 Fluorothymidine dose = 0.04 to 0.08 mCi/kg (maximum of 5 mCi +/- 10%).\n\nImaging technology: PET scan","id":"OG000","title":"FLT PET Scan"}],"paramType":"MEAN","populationDescription":"Participants who underwent the mid-therapy FLT PET scan","reportingStatus":"POSTED","timeFrame":"36 months","title":"Efficacy of FLT Flux (K-FLT) Mid-therapy in Predicting Overall Survival (OS).","type":"PRIMARY","unitOfMeasure":"mL/g/min"}